Co-Authors
This is a "connection" page, showing publications co-authored by VEERABHADRAN BALADANDAYUTHAPANI and JACK A ROTH.
Connection Strength
0.571
-
TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res. 2018 02; 6(2):163-177.
Score: 0.156
-
TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep. 2016 11 15; 6:35741.
Score: 0.143
-
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One. 2015; 10(6):e0123967.
Score: 0.130
-
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
Score: 0.105
-
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget. 2017 Jul 18; 8(29):48222-48239.
Score: 0.038